Hyd-based Startoon Labs’ physiotherapy monitoring device bags US FDA nod
Pheezee is designed to assess musculoskeletal and neuromuscular health
Startoon Labs, a Hyderabad-based ISO 13485:2016 and ISO 9001:2015 Certified medical device R&D, engineering and manufacturing company with a focus on joint health received US FDA (The US Food and Drug Administration) (510 K Exempt) clearance for its revolutionary wearable device PHEEZEE️.
The US FDA is a regulatory agency that ensures the safety and security of drugs, devices and other products going into the US Market.
Suresh Susurla, Founder and CEO said, “Pheezee is a patented technology, capable of measuring the surface Electromyogram (sEMG) of bulk muscles and Range of motion (ROM) of primary joints simultaneously, to determine joint health, making it a one-of-a-kind product in the world with this capability.”
Pheezee helps assess joint health during physiotherapy post musculoskeletal, neurological, spinal cord injuries and neuro-ailments such as paralysis, hemiplegia, paraplegia, muscular dystrophy etc. It generates reports, for the first time in the field of physiotherapy, enabling patients to track their recovery. Pheezee, being an IOT-enabled device, enables telerehabilitation of the patients and allows them to continue doing physiotherapy sessions at home and still keep the referring surgeon updated about the progress.
It is a revolutionary device set to transform the way assessments, monitoring and tracking of recovery is done in the field of physiotherapy, says Mythreyi Kondapi Co-founder of the medical technology startup.
The flagship product of the company already enjoys national and international recognition. With US FDA’s nod, its reach is going to be widened even further. Now it will demonstrate its performance in the US and many other global markets. Utilising advanced technology like Electromyography and Range of Motion monitoring, Pheezee measures and tracks the recovery of patients post musculoskeletal and neurological ailments. The device finds usage in joint health assessments in multiple musculoskeletal diseases, including arthritis, muscle dystrophy, carpal tunnel syndrome (which affects 64.4 per cent of IT professionals), and many more in their early stages.
